ALK and lung carcinoma: Molecular profiling of lung cancer samples for activated oncogenes, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and c–ros oncogene 1 (ROS1), is considered as standard-of care to select the most appropriate up-front treatment [3].